Morphea blotches clear after receiving vaccine; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Morphea blotches clear after receiving vaccine) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031H20A and 038K20A) for COVID-19 vaccination.     The patient's past medical history included Blood transfusion (Blood transfusion done because of car accident.) on 14-Sep-2018, Urinary incontinence, Depression, Cholecystectomy (gall bladder removal-seat belt injury.) and Umbilical hernia repair. Concurrent medical conditions included Influenza immunization (Flu vaccine allergy.), Food allergy (Yellow dye.), Drug allergy (Aacetazolamide.), Morphea (morphea as a result blows,) since 14-Sep-2018 and Drug allergy (Statins). Concomitant products included RIMEGEPANT SULFATE (NURTEC ODT) for Headache, ONDANSETRON (ONDASETRON [ONDANSETRON]) for Nausea, LEVOTHYROXINE SODIUM (EUTHYROX) for Thyroid disorder, METHAZOLAMIDE, PANTOPRAZOLE, LOSARTAN, VITAMIN D2, UBIDECARENONE (COQ 10), VITAMIN E NOS, PARACETAMOL (TYLENOL), IBUPROFEN, CENTRUM SILVER [ASCORBIC ACID;BETACAROTENE;BIOTIN;CALCIUM;CHROMIUM;COLECALCIFEROL;COPPER;FOLIC ACID;IODINE;IRON;LYCOPENE;MAGNESIUM;MANGANESE;NICOTINAMIDE;PANTOTHENIC ACID;PHOSPHORUS;PHYTOMENADIONE;POTASSIUM;PYRIDOXINE HYDROCHLORIDE;RETINOL;RIBOFLAVIN, CURCUMA LONGA RHIZOME, PIPER NIGRUM FRUIT (TURMERIC +), KRILL OIL and D-MANNOSE, VACCINIUM MACROCARPON (D-MANNOSE CRANBERRY EXTRA) for an unknown indication.   On 08-Feb-2021 at 6:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021 at 6:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Morphea blotches clear after receiving vaccine). The patient was treated with PREDNISONE for Morphea, at an unspecified dose and frequency; METHOTREXATE for Morphea, at an unspecified dose and frequency and HYDROXYCHLOROQUINE PHOSPHATE (PLAQUENIL [HYDROXYCHLOROQUINE PHOSPHATE]) for Morphea, at an unspecified dose and frequency. At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Morphea blotches clear after receiving vaccine) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: positive (Positive) Biopsy positive was diagnosed as Morphea.         Concomitant medication had UV light treatment & used creams, plaqvenil. Preservision Adreds2 2/day as OTC drugs in unknown dates. The action taken with mRNA-1273 with the event was considered as not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Follow up information received contains significant information. Patient demographics added, Dose first details added, second dose details and event updated. On 14-Jul-2021: Follow up information received contains significant information. Added Concomitant medications, treatment medication details and Lab data and is considered significant